AstraZeneca and Daiichi Sankyo have submitted a ... datopotamab deruxtecan as a monotherapy and in combination with other anticancer treatments in various settings. AstraZeneca and Daiichi Sankyo ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum ... as a monotherapy and in combination with other anticancer treatments in various ...
Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.
Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...
Medpage Today on MSN5d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsAn obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...
Gowling WLG won this year's LB Award for Life Sciences Team of the Year for its role in advising AstraZeneca on a ...
TOKYO, Japan & BASKING RIDGE, NJ, USA I October 30, 2024 I The first patients have been dosed in three global, randomized phase 3 trials evaluating the ...
in combination with standard cytarabine/anthracycline induction therapy and cytarabine consolidation therapy for these patients, and as maintenance monotherapy thereafter. Daiichi Sankyo says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback